
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
Cell therapy is set to transform the treatment of diseases across a diverse range of therapeutic areas. But, to meet these needs developers need to be ready to innovate and carve a path to success.







